Indivior reports Q2 2026 results and raises guidance
Indivior posted record quarterly net revenues and raised 2026 full-year guidance driven by strong SUBLOCADE performance. The company also announced a merger agreement with Supernus Pharmaceuticals.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day